- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued based on future growth
Swiss Pharmaceuticals & Biotech Undervalued based on future growth
Results
2
0 new
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
2 companies
Cosmo Pharmaceuticals
Market Cap: CHF 994.6m
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 62.40
7D
-7.6%
1Y
-3.3%
Newron Pharmaceuticals
Market Cap: CHF 283.4m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 14.20
7D
-1.7%
1Y
79.7%